‘OMUFA Fee Liable’ Trending In US OTC Drug Industry To Pay For FDA's Monograph Reform
Executive Summary
Some firms with sales in nonprescription drug space are exempt from program’s facility fees, but own-label OTC drug marketers aren’t among them. Although FDA allows fee discounts for small businesses in other areas, it’s not trimming monograph user fee rates.
You may also be interested in...
In US OTC Monograph Program, ‘FDR’ Spells Appealing FDA's Rejections Of Change Requests
Draft guidance adds “formal dispute resolution” to other terms becoming common in OTC drug sector since agency began overhaul of monograph drug program authorized in 2020. Others are OMOR, for OTC monograph order request, and OMUFA, for user fee program also authorized.
US Firm's Supplement Claims For Hangover Relief Watered Down In Industry Self-Regulation Review
More Labs’ online claims might not be distilled satisfactorily for FDA’s taste for dietary supplement claims for hangover help agency made known a year ago. Firm will narrow claim suggesting its products could broadly relieve hangover symptoms.
OTC DFL ‘Remains Static, Non-Customizable Tool’ As US FDA Lifts Curtain On Potential Changes
Webinar on DFL requirements was a good launch toward potential changes, says CDER Office of Nonprescription Drugs Director Theresa Michele, "This is a great opportunity for us. I think we are on the cusp of a lot of neat things in the OTC marketplace."